ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1959

Epidemiology of Hospitalizations and Associated Mortality in Vasculitis: A National Study
Abstract Number: 1960

Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
Abstract Number: 1961

Decreased Visits in RISE Practices Due to the SARS-CoV-2 Global Pandemic
Abstract Number: 1962

Utilization of Telehealth Among Patients with Rheumatic Diseases in the Early Months of the COVID-19 Pandemic
Abstract Number: 1963

Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices
Abstract Number: 1964

Engaging Patients in the Development of a Quality Measure of Functional Status to Improve Care Among Patients with Rheumatoid Arthritis
Abstract Number: 1965

Reducing Delays for Biologic Medication Approval in Outpatient Rheumatology
Abstract Number: 1966

Improving Value Concordant Care Through Increased Use of Subcutaneous Methotrexate in Rheumatoid Arthritis
Abstract Number: 1967

Combating Rheumatologist Burnout: Use of Protocol Driven Medication Refill by Pharmacists
Abstract Number: 1968

Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Abstract Number: 1969

The Dynamics of Macrophage Sub-Populations in the Inflammatory Phase Following Joint Trauma
Abstract Number: 1970

Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model
Abstract Number: 1971

Gut Microbiome Transplantation from MRL/MpJ Mice Prevents Post-Traumatic Osteoarthritis in C57BL6/J Mice
Abstract Number: 1972

NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis
Abstract Number: 1973

Treatment Sequences with Romosozumab Before or After Antiresorptive Medication

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].